- Home
- SANA vs RLAY Comparison
SANA vs RLAY Comparison
Compare SANA & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANA
- RLAY
- Stock Information
- Founded
- SANA 2018
- RLAY 2015
- Country
- SANA United States
- RLAY United States
- Employees
- SANA N/A
- RLAY N/A
- Industry
- SANA Medicinal Chemicals and Botanical Products
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SANA Health Care
- RLAY Health Care
- Exchange
- SANA Nasdaq
- RLAY Nasdaq
- Market Cap
- SANA 489.5M
- RLAY 490.3M
- IPO Year
- SANA 2021
- RLAY 2020
- Fundamental
- Price
- SANA $2.61
- RLAY $3.18
- Analyst Decision
- SANA Strong Buy
- RLAY Strong Buy
- Analyst Count
- SANA 5
- RLAY 11
- Target Price
- SANA $9.50
- RLAY $18.40
- AVG Volume (30 Days)
- SANA 4.1M
- RLAY 1.6M
- Earning Date
- SANA 08-07-2025
- RLAY 08-05-2025
- Dividend Yield
- SANA N/A
- RLAY N/A
- EPS Growth
- SANA N/A
- RLAY N/A
- EPS
- SANA N/A
- RLAY N/A
- Revenue
- SANA N/A
- RLAY $7,679,000.00
- Revenue This Year
- SANA N/A
- RLAY $14.31
- Revenue Next Year
- SANA N/A
- RLAY N/A
- P/E Ratio
- SANA N/A
- RLAY N/A
- Revenue Growth
- SANA N/A
- RLAY N/A
- 52 Week Low
- SANA $1.26
- RLAY $1.78
- 52 Week High
- SANA $7.40
- RLAY $10.72
- Technical
- Relative Strength Index (RSI)
- SANA 57.21
- RLAY 55.48
- Support Level
- SANA $2.41
- RLAY $2.98
- Resistance Level
- SANA $2.97
- RLAY $3.48
- Average True Range (ATR)
- SANA 0.26
- RLAY 0.25
- MACD
- SANA -0.00
- RLAY -0.00
- Stochastic Oscillator
- SANA 52.04
- RLAY 58.45
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).